| A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia (NCT05609825) | Eli Lilly and Company | 2022-11-14 |
| A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). (NCT05620576) | Eli Lilly and Company | 2022-11-14 |
| A Relative Bioavailability Study of LY3209590 in Healthy Participants (NCT05615532) | Eli Lilly and Company | 2022-11-11 |
| A Study of LY3457263 in Obese Participants (NCT05582096) | Eli Lilly and Company | 2022-11-11 |
| A Drug Interaction Study of LY3871801 in Healthy Participants (NCT05602675) | Eli Lilly and Company | 2022-11-02 |
| A Study of LY3437943 in Chinese Participants With Obesity Or Overweight (NCT05548231) | Eli Lilly and Company | 2022-10-24 |
| A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] (NCT05565742) | Eli Lilly and Company | 2022-10-20 |
| A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (NCT05559359) | Eli Lilly and Company | 2022-10-18 |
| A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants (NCT05573230) | Eli Lilly and Company | 2022-10-17 |
| A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) (NCT05508789) | Eli Lilly and Company | 2022-10-10 |
| A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer (NCT05509790) | Eli Lilly and Company | 2022-10-09 |
| A Study of Donanemab (LY3002813) in Healthy Participants (NCT05567159) | Eli Lilly and Company | 2022-10-04 |
| A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (NCT05514054) | Eli Lilly and Company | 2022-10-04 |
| CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma (NCT05440786) | Eli Lilly and Company | 2022-09-20 |
| A Study of Donanemab (LY3002813) in Healthy Chinese Participants (NCT05533411) | Eli Lilly and Company | 2022-09-14 |
| A Study of Imlunestrant (LY3484356) in Healthy Women (NCT05509816) | Eli Lilly and Company | 2022-09-12 |
| A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (NCT05516758) | Eli Lilly and Company | 2022-08-31 |
| A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants (NCT05515601) | Eli Lilly and Company | 2022-08-31 |
| A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (NCT05463744) | Eli Lilly and Company | 2022-08-12 |
| A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis (NCT05486208) | Eli Lilly and Company | 2022-08-11 |
| A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (NCT05462756) | Eli Lilly and Company | 2022-08-11 |
| A Study of LY3873862 in Healthy Participants (NCT05492201) | Eli Lilly and Company | 2022-08-11 |
| A Study of LY3537021 in Healthy Participants (NCT05444569) | Eli Lilly and Company | 2022-08-08 |
| A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (NCT05433584) | Eli Lilly and Company | 2022-08-01 |
| A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) (NCT05463731) | Eli Lilly and Company | 2022-08-01 |
| A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants (NCT05469126) | Eli Lilly and Company | 2022-08-01 |
| A Study of LY3561774 in Participants With Mixed Dyslipidemia (NCT05256654) | Eli Lilly and Company | 2022-07-20 |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants (NCT05445232) | Eli Lilly and Company | 2022-07-08 |
| A Study of Imlunestrant (LY3484356) in Female Healthy Participants (NCT05444556) | Eli Lilly and Company | 2022-07-07 |
| A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function (NCT05440344) | Eli Lilly and Company | 2022-07-05 |
| A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants (NCT05440136) | Eli Lilly and Company | 2022-06-28 |
| Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004) | Eli Lilly and Company | 2022-06-21 |
| A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (NCT05395481) | Eli Lilly and Company | 2022-06-08 |
| A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (NCT05377333) | Eli Lilly and Company | 2022-06-02 |
| A Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05313802) | Eli Lilly and Company | 2022-05-26 |
| A Study of Two Different Formulations of LY3502970 in Healthy Participants (NCT05341089) | Eli Lilly and Company | 2022-05-17 |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (NCT05307705) | Eli Lilly and Company | 2022-05-11 |
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (NCT05288166) | Eli Lilly and Company | 2022-04-14 |
| A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (NCT05260021) | Eli Lilly and Company | 2022-04-13 |
| A Study of LY3841136 in Healthy and Overweight Participants (NCT05295940) | Eli Lilly and Company | 2022-03-30 |
| A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes (NCT04992312) | Eli Lilly and Company | 2022-03-24 |
| A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (NCT05241834) | Eli Lilly and Company | 2022-03-23 |
| A Study of LY3857210 in Healthy Participants (NCT05292040) | Eli Lilly and Company | 2022-03-17 |
| Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (NCT05169567) | Eli Lilly and Company | 2022-03-11 |
| A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (NCT05275400) | Eli Lilly and Company | 2022-03-08 |
| A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (NCT05123586) | Eli Lilly and Company | 2022-03-07 |
| A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes (NCT05262387) | Eli Lilly and Company | 2022-02-14 |
| A Study of LY3871801 in Healthy Participants (NCT05222399) | Eli Lilly and Company | 2022-02-04 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain (NCT05177094) | Eli Lilly and Company | 2022-01-26 |
| Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants (NCT05205447) | Eli Lilly and Company | 2022-01-05 |
| A Study of Baricitinib (LY3009104) in Children With COVID-19 (NCT05074420) | Eli Lilly and Company | 2021-12-21 |
| A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT04819100) | Eli Lilly and Company | 2021-12-20 |
| A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine (NCT05127486) | Eli Lilly and Company | 2021-12-06 |
| A Study of Two Formulations (Both Refrigerated and Room Temperature) Using an Autoinjector Device in Healthy Participants (NCT05154968) | Eli Lilly and Company | 2021-11-24 |
| A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) (NCT05108922) | Eli Lilly and Company | 2021-11-16 |
| A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445) | Eli Lilly and Company | 2021-11-12 |
| A Study of LY3473329 in Healthy Japanese Participants (NCT05038787) | Eli Lilly and Company | 2021-11-11 |
| A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants (NCT05042310) | Eli Lilly and Company | 2021-11-11 |
| A Multiple-Dose Study of LY3502970 in Healthy Participants (NCT05110794) | Eli Lilly and Company | 2021-11-05 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain (NCT05086289) | Eli Lilly and Company | 2021-10-25 |
| A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus (NCT05067270) | Eli Lilly and Company | 2021-10-22 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis (NCT05080660) | Eli Lilly and Company | 2021-10-12 |
| A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants (NCT06181084) | Eli Lilly and Company | 2021-10-11 |
| A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants (NCT05069896) | Eli Lilly and Company | 2021-10-05 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities (NCT05051579) | Eli Lilly and Company | 2021-09-29 |
| A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants (NCT06258174) | Eli Lilly and Company | 2021-09-28 |
| A Device Study in Healthy Participants (NCT04848402) | Eli Lilly and Company | 2021-09-27 |
| A Multiple Dose Study of LY3502970 in Healthy Participants (NCT05051566) | Eli Lilly and Company | 2021-09-16 |
| A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease (NCT05063539) | Eli Lilly and Company | 2021-09-16 |
| A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus (NCT05048719) | Eli Lilly and Company | 2021-09-15 |
| A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) (NCT05024032) | Eli Lilly and Company | 2021-09-01 |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) (NCT05026866) | Eli Lilly and Company | 2021-08-27 |
| A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes (NCT04864977) | Eli Lilly and Company | 2021-08-16 |
| A Study of LY3361237 in Participants With Psoriasis (NCT04975295) | Eli Lilly and Company | 2021-07-27 |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (NCT04956640) | Eli Lilly and Company | 2021-07-19 |
| A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus (NCT04957914) | Eli Lilly and Company | 2021-07-14 |
| A Study of LY3819469 in Healthy Participants (NCT04914546) | Eli Lilly and Company | 2021-06-14 |
| A Study of LY3532226 in Healthy Participants (NCT04923269) | Eli Lilly and Company | 2021-06-10 |
| A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction (NCT04840914) | Eli Lilly and Company | 2021-06-01 |
| A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) (NCT04844606) | Eli Lilly and Company | 2021-05-26 |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) (NCT04823208) | Eli Lilly and Company | 2021-05-24 |
| A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760) | Eli Lilly and Company | 2021-05-20 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants (NCT04881747) | Eli Lilly and Company | 2021-05-14 |
| A Study of LY3437943 in Participants With Type 2 Diabetes (NCT04867785) | Eli Lilly and Company | 2021-05-13 |
| A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (NCT04752332) | Eli Lilly and Company | 2021-05-10 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain (NCT04707157) | Eli Lilly and Company | 2021-05-06 |
| A Study of LY3493269 in Healthy Participants (NCT04682106) | Eli Lilly and Company | 2021-05-03 |
| A Study of LY3484356 in Healthy Female Participants (NCT04840888) | Eli Lilly and Company | 2021-04-26 |
| A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (NCT04647487) | Eli Lilly and Company | 2021-04-21 |
| A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557) | Eli Lilly and Company | 2021-04-20 |
| A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (NCT04469062) | Eli Lilly and Company | 2021-04-20 |
| A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes (NCT04809220) | Eli Lilly and Company | 2021-04-13 |
| A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (NCT04527380) | Eli Lilly and Company | 2021-04-13 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003) | Eli Lilly and Company | 2021-03-29 |
| A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016) | Eli Lilly and Company | 2021-03-29 |
| A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (NCT04660643) | Eli Lilly and Company | 2021-03-29 |
| A Study of LY3540378 in Healthy Participants (NCT04768855) | Eli Lilly and Company | 2021-03-17 |
| A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (NCT04760314) | Eli Lilly and Company | 2021-03-10 |